{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:41:04Z","timestamp":1769838064951,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T00:00:00Z","timestamp":1340064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To quantify the incidence of osteonecrosis of the jaw (ONJ) by bisphosphonate exposure among two cohorts of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a retrospective cohort study, we identified cohort members via health insurance claim diagnosis codes and identified potential cases of ONJ that were confirmed with medical record review. One cohort included patients aged \u226540\u2009years with breast or prostate cancer or multiple myeloma; the other cohort included men aged \u226560\u2009years and women \u226550\u2009years with osteoporosis. For each cohort, we calculated sex\u2010 and age\u2010standardized incidence of ONJ by exposure to oral bisphosphonates and intravenous bisphosphonates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the cancer cohort (<jats:italic>n<\/jats:italic>\u2009=\u200946\u2009542), sex\u2010 and age\u2010standardized incidence of ONJ (<jats:italic>n<\/jats:italic>\u2009=\u200926 probable or possible cases) adjusted for abstraction proportion was 0.29 per 1000 person\u2010years (95% confidence interval [CI], 0.07\u20130.52) among those unexposed to bisphosphonates and 5.3 (95%CI, 1.9\u20138.7) after intravenous bisphosphonate use. Controlling for covariates, the rate ratio for intravenous use versus no use was 8.8 (95%CI, 2.0\u201338). Patients with multiple myeloma had a rate 4.5 times that of patients with breast cancer.<\/jats:p><jats:p>In the osteoporosis cohort (<jats:italic>n<\/jats:italic>\u2009=\u200931\u2009244), sex\u2010 and age\u2010standardized ONJ (<jats:italic>n<\/jats:italic>\u2009=\u200911 probable or possible cases) incidence was 0.26 per 1000 person\u2010years (95%CI, 0.06\u20130.47) among those unexposed to bisphosphonate and 0.15 (95%CI, 0.00\u20130.36) after oral bisphosphonate use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Among patients with selected cancers, incidence of ONJ was higher among those with multiple myeloma and users of intravenous bisphosphonates. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3292","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T15:03:09Z","timestamp":1340118189000},"page":"810-817","source":"Crossref","is-referenced-by-count":64,"title":["Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis"],"prefix":"10.1002","volume":"21","author":[{"given":"Patricia","family":"Tennis","sequence":"first","affiliation":[{"name":"Epidemiology RTI Health Solutions, Research Triangle Park  North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[{"name":"Epidemiology RTI Health Solutions, Research Triangle Park  North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhonda L.","family":"Bohn","sequence":"additional","affiliation":[{"name":"Safety HealthCore, Inc.  Wilmington Delaware USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiangkiat","family":"Tan","sequence":"additional","affiliation":[{"name":"Safety HealthCore, Inc.  Wilmington Delaware USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Zavras","sequence":"additional","affiliation":[{"name":"Oral Epidemiology Columbia University  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Laskarides","sequence":"additional","affiliation":[{"name":"Oral &amp; Maxillofacial Surgery Tufts University  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Calingaert","sequence":"additional","affiliation":[{"name":"Epidemiology RTI Health Solutions, Research Triangle Park  North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary S.","family":"Anthony","sequence":"additional","affiliation":[{"name":"Global Biostatistics and Epidemiology Amgen, Inc.  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,6,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.01.009"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2005.07.010"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21130"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2008.0016"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm025"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2006.02.011"},{"key":"e_1_2_7_9_1","volume-title":"Analytic methods","author":"Harvard College","year":"2004"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang KY","year":"1986","journal-title":"Biometrika"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1947"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9584"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2007.03.006"},{"key":"e_1_2_7_14_1","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos MA","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080205"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2010.05876.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-1862-z"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3292","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:40:32Z","timestamp":1698644432000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,19]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1002\/pds.3292"],"URL":"https:\/\/doi.org\/10.1002\/pds.3292","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,19]]}}}